Sudarshan Pharma Industries Limited (BOM:543828)
India · Delayed Price · Currency is INR 39.42
+0.40 (1.03%)
At close: Sep 4, 2026
BOM:543828 Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 7,322 | 7,031 | 5,050 | 4,635 | 4,613 | 3,571 |
| 7,322 | 7,031 | 5,050 | 4,635 | 4,613 | 3,571 | |
Revenue Growth | 32.86% | 39.21% | 8.95% | 0.48% | 29.19% | 84.52% |
Cost of Revenue | 6,399 | 6,196 | 4,398 | 4,226 | 4,310 | 3,354 |
Gross Profit | 923.03 | 834.87 | 651.92 | 409.86 | 303.72 | 217.06 |
Selling, General & Admin | 79.21 | 86.37 | 59.66 | 47.49 | 41.93 | 30.82 |
Other Operating Expenses | 282.11 | 225.75 | 190.71 | 125.44 | 109.59 | 76.08 |
Operating Expenses | 404.43 | 350 | 278.42 | 185.38 | 160.59 | 115.56 |
Operating Income | 518.6 | 484.87 | 373.5 | 224.48 | 143.12 | 101.5 |
Interest Expense | -279.5 | -228.56 | -140.32 | -78.7 | -45.86 | -27.58 |
Interest & Investment Income | - | 20.21 | 5.55 | 7.88 | 4.9 | 1.99 |
Currency Exchange Gain (Loss) | - | 22.05 | -2.01 | 1.95 | 0.13 | 0.11 |
Other Non Operating Income (Expenses) | 87.26 | -3.36 | -8.76 | -3.33 | -4.95 | -3.67 |
EBT Excluding Unusual Items | 326.36 | 295.2 | 227.96 | 152.28 | 97.34 | 72.35 |
Gain (Loss) on Sale of Assets | - | 10.2 | - | - | -2.37 | -0.99 |
Other Unusual Items | - | - | -28.17 | - | - | - |
Pretax Income | 326.36 | 305.4 | 199.79 | 152.28 | 94.96 | 71.36 |
Income Tax Expense | 76.13 | 71.68 | 50.52 | 37.73 | 24.6 | 18.87 |
Earnings From Continuing Operations | 250.23 | 233.72 | 149.27 | 114.55 | 70.37 | 52.49 |
Minority Interest in Earnings | 0.99 | -0.68 | 0.02 | - | - | -0.01 |
Net Income | 251.22 | 233.03 | 149.3 | 114.55 | 70.37 | 52.48 |
Net Income to Common | 251.22 | 233.03 | 149.3 | 114.55 | 70.37 | 52.48 |
Net Income Growth | 18.94% | 56.09% | 30.33% | 62.79% | 34.09% | 96.46% |
Shares Outstanding (Basic) | 241 | 241 | 241 | 239 | 241 | 144 |
Shares Outstanding (Diluted) | 241 | 244 | 242 | 239 | 241 | 144 |
Shares Change | -0.99% | 0.59% | 1.45% | -0.83% | 66.88% | -5.63% |
EPS (Basic) | 1.04 | 0.97 | 0.62 | 0.48 | 0.29 | 0.36 |
EPS (Diluted) | 1.04 | 0.97 | 0.62 | 0.48 | 0.29 | 0.36 |
EPS Growth | 20.14% | 56.18% | 29.17% | 64.16% | -19.65% | 108.19% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -713.96 | -535.69 | 59.02 | -431.2 | -54.79 |
Free Cash Flow Per Share | - | -2.93 | -2.21 | 0.25 | -1.79 | -0.38 |
Dividend Per Share | - | - | - | - | 0.030 | - |
Dividend Growth | - | - | - | - | - | - |
Gross Margin | 12.61% | 11.88% | 12.91% | 8.84% | 6.58% | 6.08% |
Operating Margin | 7.08% | 6.90% | 7.40% | 4.84% | 3.10% | 2.84% |
Profit Margin | 3.43% | 3.31% | 2.96% | 2.47% | 1.52% | 1.47% |
Free Cash Flow Margin | - | -10.15% | -10.61% | 1.27% | -9.35% | -1.53% |
EBITDA | 563.38 | 509.4 | 391.11 | 236.77 | 152.19 | 110.15 |
EBITDA Margin | 7.69% | 7.25% | 7.74% | 5.11% | 3.30% | 3.08% |
D&A For EBITDA | 44.78 | 24.54 | 17.61 | 12.29 | 9.07 | 8.66 |
EBIT | 518.6 | 484.87 | 373.5 | 224.48 | 143.12 | 101.5 |
EBIT Margin | 7.08% | 6.90% | 7.40% | 4.84% | 3.10% | 2.84% |
Effective Tax Rate | 23.33% | 23.47% | 25.28% | 24.78% | 25.90% | 26.45% |
Revenue as Reported | 7,409 | 7,118 | 5,077 | 4,661 | 4,624 | 3,576 |
Advertising Expenses | - | 0.17 | 0.21 | 0.28 | 0.07 | 0.04 |